Literature DB >> 11676862

Antitumor effect of the idiotypic cascade induced by an antibody encapsulated in poly(d,l-lactide-co-glycolide) microspheres.

J Ma1, D Luo, W Qi, L Cao.   

Abstract

A major difficulty encountered during development of antibody vaccines is their weak immunogenicity. In this study, a monoclonal antibody CS20.5 to human breast cancer antigen CA15.3 was coencapsulated in poly(d,l-lactide-co-glycolide) microspheres with monophosphoryl lipid A. The antitumor effect of this formulation was investigated in a murine model. The induced Ab2 biologically mimics antigen as it competed with CA15.3 for the same idiotope on Ab1. Ab3 induction was also observed. After five sequential administrations of encapsulated antibody, mice showed statistically significant tumor regression. These results indicate that this formulation may serve as a potential treatment for breast cancer.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11676862      PMCID： PMC5926615          DOI： 10.1111/j.1349-7006.2001.tb01066.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


  23 in total

1.  Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72.

Authors:  I Blanco; R Kawatsu; K Harrison; P Leichner; S Augustine; J Baranowska-Kortylewicz; M Tempero; D Colcher
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

2.  Monoclonal antibodies and their role in modulation of the immune response.

Authors:  M Arlen; K Y Tsang
Journal:  J Surg Oncol       Date:  1993-10       Impact factor: 3.454

3.  Particle size studies for subcutaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation.

Authors:  T Uchida; S Goto; T P Foster
Journal:  J Pharm Pharmacol       Date:  1995-07       Impact factor: 3.765

Review 4.  Potential of polymer microencapsulation technology for vaccine innovation.

Authors:  W Morris; M C Steinhoff; P K Russell
Journal:  Vaccine       Date:  1994-01       Impact factor: 3.641

5.  Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection.

Authors:  J A Whittum-Hudson; L L An; W M Saltzman; R A Prendergast; A B MacDonald
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

6.  Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?

Authors:  J Fagerberg; J E Frödin; H Wigzell; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

7.  Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes.

Authors:  J Fagerberg; A L Hjelm; P Ragnhammar; J E Frödin; H Wigzell; H Mellstedt
Journal:  Cancer Res       Date:  1995-05-01       Impact factor: 12.701

8.  Stabilization of tetanus toxoid in poly(DL-lactic-co-glycolic acid) microspheres for the controlled release of antigen.

Authors:  A C Chang; R K Gupta
Journal:  J Pharm Sci       Date:  1996-02       Impact factor: 3.534

9.  Murine monoclonal IgG antibodies: differences in their IgG isotypes can affect the antibody effector activity when using human cells.

Authors:  P I Lobo; H C Patel
Journal:  Immunol Cell Biol       Date:  1997-06       Impact factor: 5.126

10.  [FAB immunoglobulin fragments. I. The comparative characteristics of the serological and virus-neutralizing properties of a gamma globulin against tick-borne encephalitis and of the FAB fragments isolated from it].

Authors:  P S Barban; V M Minaeva; A N Pantiukhina; M G Startseva
Journal:  Zh Mikrobiol Epidemiol Immunobiol       Date:  1976-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.